ClinicalTrials.gg
CompletedNCT04221321Updated Dec 1, 2020

Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers

A Phase 1 interventional study of Atorvastatin 40 mg and Tegoprazan 50 mg in Healthy, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-01.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

This study aims to evaluate the influence of tegoprazan or RAPA114 on the Pharmacokinetic characteristics of atorvastatin following co-administration of tegoprazan or RAPA114 in healthy adult volunteers.

Read the detailed description

[Pharmacokinetic Assessments] : Blood concentration of atorvastatin, 2-OH atorvastatin

  • Primary outcome: AUCτ, Css,max of atorvastatin
  • Secondary outcome: Tss,max of atorvastatin, AUCτ, Css,max of 2-OH atorvastatin, metabolic ratio

[Sefety Assessments]

: Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory test

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male adults aged 19 to 55 years (inclusive) at the time of his consent.
  • (BMI) ≥ 19.0 and ≤ 27.0 kg/m2 at screening.
  • Decides to participate voluntarily in the trial after being fully informed of and understanding the study completely, and provides the written to participate in the trial and to comply with the trial-specific requirements.
  • Has the ability and willingness to participate in the entire period of clinical trial.

Exclusion criteria

Exclusion Criteria:

  • A subject with disease or history of hepatobiliary, renal, gastrointestinal, cardiovascular, musculoskeletal, endocrine, respiratory, neuropsychiatry or hemato-oncologic system, etc.
  • A subject with a history of reactions to main constituents of or identical affiliation of the products (ex, HMG-CoA reductase inhibitor, gastric acid suppressants), or have allergic diseases that require treatment.
  • A subject with a history of genetic myopathy or family history.
  • A subject who has participated in other clinical trials and received the investigational products within 180 days prior to the randomization.
  • A subject who received any medications or foods that could significantly affect the absorption, distribution, metabolism, or excretion of an investigational product within 30 days prior to the randomization.
  • A subject with history of whole blood donation within 60 days, or with blood components or received transfusion within 30 days prior to the randomization.
  • A subject with continued consumption of alcohol more than 140 g per week.
  • A subject with , ALT, or γ-GT levels exceeding 1.5 times of the upper limit of the reference range in the screening test.
  • A subject with a calculated of less than 60 mL / min / 1.73 m2 in the screening test.
  • A subject with any positive result on serology tests for , , or syphilis in the screening test.
  • A subject with galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose-galactose malabsorption, etc.
  • Male subject who don't have willing to accept medically acceptable methods during the course of clinical trial, or who plan to provide sperm.
  • A subject who is determined to be ineligible to participate in the clinical trial by the investigator for other reasons.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Placebo comparator
    Atorvastatin 40 mg

    Oral administration of Atorvastatin 40 mg tablet once daily for 7 days

    Drug: Atorvastatin 40 mg

  • Experimental
    Atorvastatin 40 mg + Tegoprazan 50 mg

    Oral administration of Atorvastatin 40 mg tablet and Tegoprazan 50 mg tablet once daily for 7 days

    Drug: Atorvastatin 40 mg · Drug: Tegoprazan 50 mg

  • Active comparator
    Atorvastatin 40 mg + RAPA114

    Oral administration of Atorvastatin 40 mg tablet and RAPA114 tablet once daily for 7 days

    Drug: Atorvastatin 40 mg · Drug: RAPA114

Interventions

06

What researchers measure

Primary outcomes

  1. AUCτ of atorvastatin

    Area under the plasma drug concentration-time curve at steady state

    Time frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period

  2. Css,max of atorvastatin

    Maximum concentration of drug in plasma of atorvastatin at steady state

    Time frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period

Secondary outcomes

  1. Tss,max of atorvastatin

    Time to Cmax at steady state

    Time frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period

  2. AUCτ of 2-OH atorvastatin

    Area under the plasma drug concentration-time curve at steady state

    Time frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period

  3. Css,max of 2-OH atorvastatin

    Maximum concentration of drug in plasma of 2-OH atorvastatin at steady state

    Time frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period

  4. metabolic ratio

    AUCτ of 2-OH atorvastatin / AUCτ of atorvastatin

    Time frame: Pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in each period

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Mar 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2020
First posted
Jan 9, 2020
StartActual
Jan 7, 2020
Primary completionActual
Mar 12, 2020
CompletionActual
Apr 20, 2020
Last update
Dec 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04221321
Responsible party
Sponsor
First posted
Jan 9, 2020
Start date
Jan 7, 2020
Primary completion
Mar 12, 2020
Completion
Apr 20, 2020
Last update
Dec 1, 2020

Study contacts

Jung-ryul Kim
principal investigator · Samsung Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Tegoprazan

Start the discussion